This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr McKenzie and colleagues¹ suggest that hydrocortisone, despite its effectiveness against chronic fatigue syndrome (CFS), should not be used as a prolonged treatment for CFS because they found that "cautious hormonal supplementation" consisting of "low-dose" hydrocortisone caused a significant degree of adrenal suppression. Such suppression, however, may simply indicate that the dosage of hydrocortisone was neither cautiously low nor suitable for CFS patients. Hydrocortisone in dosages greater than 22 mg/d may harm even subjects with bilateral adrenalectomies,² whose adrenal insufficiency is axiomatically absolute. Therefore, the 25- to 35-mg/d hydrocortisone dosage administered by McKenzie et al clearly represents an inappropriately high dosage for CFS patients, whose adrenal insufficiency is mild, since those authors report that "CFS patients excreted, on average, about 30% less cortisol in 24-hour urine collections than healthy, matched controls."¹

During the twice-daily regimen of glucocorticoid replacement therapy, the second daily dose is usually administered in . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Fibromyalgia, Chronic Fatigue Syndrome, and Addison Disease
Baschetti
Arch Intern Med 1999;159:2481-2481.
FULL TEXT